Designer vaccine nanodiscs for personalized cancer immunotherapy

Nature Materials

Volumn 16, Issue 4, 2017, Pages 489-498

  Kuai, Rui ^a   Ochyl, Lukasz J ^a   Bahjat, Keith S ^b   Schwendeman, Anna ^a   Moon, James J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Bristol Myers Squibb   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; EPITOPES; MEDICAL NANOTECHNOLOGY; PEPTIDES; T-CELLS; TUMORS;

CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTES; DENDRITIC CELLS; GENERAL METHODOLOGIES; HIGH DENSITY LIPOPROTEIN; PATIENT SPECIFIC; PERSONALIZED NANOMEDICINE; T-CELL RESPONSE;

VACCINES;

CANCER VACCINE; EPITOPE; NANOMATERIAL; TUMOR ANTIGEN;

ANIMAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; IMMUNOLOGY; MOUSE; PATHOLOGY; TUMOR CELL LINE; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPES; FEMALE; HUMANS; IMMUNITY, CELLULAR; MICE; NANOSTRUCTURES; NEOPLASMS, EXPERIMENTAL; VACCINATION;

EID: 85019121583     PISSN: 14761122     EISSN: 14764660     Source Type: Journal    
DOI: 10.1038/NMAT4822     Document Type: Article

References (50)

1. Melief, C. J. & van der Burg, S. H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8, 351-360 (2008).
2. Speiser, D. E. et al. Rapid and strong human CD8C T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115, 739-746 (2005).
3. Fourcade, J. et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8C T cells in melanoma patients. J. Immunother. 31, 781-791 (2008).
4. Hailemichael, Y. et al. Persistent antigen at vaccination sites induces tumor-specific CD8C T cell sequestration, dysfunction and deletion. Nat. Med. 19, 465-472 (2013).
5. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159-1164 (2007).
6. Moon, J. J. et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater. 10, 243-251 (2011).
7. Lee, I. H. et al. Imageable antigen-presenting gold nanoparticle vaccines for e_ective cancer immunotherapy in vivo. Angew Chem. Int. Ed. 51, 8800-8805 (2012).
8. Li, A. V. et al. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci. Transl. Med. 5, 204ra130 (2013).
9. Jeanbart, L. et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol. Res. 2, 436-447 (2014).
10. Xu, Z., Wang, Y., Zhang, L. & Huang, L. Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano 8, 3636-3645 (2014).
11. Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519-522 (2014).
12. Rosalia, R. A. et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials 40, 88-97 (2015).
13. Chiu, Y. C., Gammon, J. M., Andorko, J. I., Tostanoski, L. H. & Jewell, C. M. Modular vaccine design using carrier-free capsules assembled from polyionic immune signals. ACS Biomater. Sci. Eng. 1, 1200-1205 (2015).
14. Fan, Y. & Moon, J. J. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines (Basel)3, 662-685 (2015).
15. Lizotte, P. H. et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat. Nanotech. 13, 295-303 (2016).
16. Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572-576 (2014).
17. Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692-696 (2015).
18. Rajasagi, M. et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 124, 453-462 (2014).
19. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
20. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149-1157 (2007).
21. Fischer, N. O. et al. Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens. J. Am. Chem. Soc. 135, 2044-2047 (2013).
22. Duivenvoorden, R. et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun. 5, 3065 (2014).
23. Li, D., Gordon, S., Schwendeman, A. & Remaley, A. T. Apolipoprotein Mimetics in the Management of Human Disease 29-42 (Springer, 2015).
24. Khan, M., Lalwani, N., Drake, S., Crockatt, J. & Dasseux, J. Single-dose intravenous infusion of ETC-642, a 22-Mer ApoA-I analogue and phospholipids complex, elevates HDL-C in atherosclerosis patients. Circulation 108, 563-564 (2003).
25. Miles, J. et al. Single-dose tolerability, pharmacokinetics, and cholesterol mobilization in HDL-C fraction following intravenous administration of ETC-642, a 22-mer ApoA-I analogue and phospholipids complex, in atherosclerosis patients. Proc. Arterioscler. Thromb. Vasc. Biol. 24, E19 (2004).
26. Kuai, R., Li, D., Chen, Y. E., Moon, J. J. & Schwendeman, A. High-density lipoproteins: Nature's multifunctional nanoparticles. ACS Nano 10, 3015-3041 (2016).
27. Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors a_ecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharmacol. 5, 505-515 (2008).
28. Anselmo, A. C. & Mitragotri, S. A review of clinical translation of inorganic nanoparticles. AAPS J. 17, 1041-1054 (2015).
29. Hirosue, S., Kourtis, I. C., van der Vlies, A. J., Hubbell, J. A. & Swartz, M. A. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation. Vaccine 28, 7897-7906 (2010).
30. Saini, S. K. et al. Dipeptides promote folding and peptide binding of MHC class I molecules. Proc. Natl Acad. Sci. USA 110, 15383-15388 (2013).
31. US National Library of Medicine ClinicalTrials.gov [online] (2009); http://clinicaltrials.gov/show/NCT00819806 (Accessed 9 January 2015).
32. US National Library of Medicine ClinicalTrials.gov [online] (2008); http://clinicaltrials.gov/ct2/show/record/NCT00640861 (Accessed 9 January 2015).
33. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
34. Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324 (2016).
35. Verdegaal, E. M. et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 536, 91-95 (2016).
36. Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. http://dx.doi.org/10.1038/nm.4200 (2016).
37. Formenti, S. C. & Demaria, S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl. Cancer Inst. 105, 256-265 (2013).
38. Kang, T. H. et al. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res. 73, 2493-2504 (2013).
39. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
40. Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747-752 (2013).
41. Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4C T cells in human melanoma. Nat. Med. 21, 81-85 (2015).
42. Kuai, R. et al. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. Mol. Pharmacol. 7, 1816-1826 (2010).
43. Lutz, M. B. et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223, 77-92 (1999).
44. DeMuth, P. C., Moon, J. J., Suh, H., Hammond, P. T. & Irvine, D. J. Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery. ACS Nano 6, 8041-8051 (2012).
45. Gorrin-Rivas, M. J. et al. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin. Cancer Res. 6, 1647-1654 (2000).
46. Ochyl, L. J. & Moon, J. J.Whole-animal imaging and flow cytometric techniques for analysis of antigen-specific CD8C T cell responses after nanoparticle vaccination. J. Vis. Exp. 98, e52771 (2015).
47. Fan, Y., Sahdev, P., Ochyl, L. J., J, J. A. & Moon, J. J. Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens. J. Control Release 208, 121-129 (2015).
48. Ning, N. et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 72, 1853-1864 (2012).
49. Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A. & Irvine, D. J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16, 1035-1041 (2010).
50. Anthony, D. D. & Lehmann, P. V. T-cell epitope mapping using the ELISPOT approach. Methods 29, 260-269 (2003).